What Indivior does

Indivior is a specialty pharmaceutical company singularly focused on developing and commercializing treatments for opioid use disorder (OUD). The company markets a portfolio of buprenorphine-based medications including SUBLOCADE (once-monthly extended-release subcutaneous injection), SUBOXONE (buprenorphine/naloxone sublingual film and tablet), SUBUTEX (buprenorphine sublingual tablets in international markets), and OPVEE (nalmefene nasal spray for opioid overdose reversal, for which sales and marketing support are being discontinued in 2025). Indivior holds an estimated 75% market share in the long-acting injectable (LAI) segment for OUD treatment, has treated approximately 191,600 U.S. SUBLOCADE patients over the trailing twelve months ending Q1 2026, and reports that 2 million people have cumulatively received buprenorphine medication-assisted treatment (BMAT) across its portfolio. The company was incorporated in 2014 ahead of its demerger from Reckitt Benckiser (which established the original Buprenorphine Business Group in 1994), completed a redomiciliation from the UK to the United States (Delaware) effective January 26, 2026, and now trades exclusively on Nasdaq under the ticker INDV.

The company's core technology centers on SUBLOCADE's extended-release depot injection platform, which forms a solid mass of buprenorphine upon contact with body fluids following subcutaneous administration, providing continuous medication release over a one-month period. SUBLOCADE is supported by an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) program that restricts dispensing to certified healthcare settings and pharmacies, creating both a safety infrastructure and a structural barrier to generic substitution. Indivior also operates clinical pharmacology modeling and an extensive real-world evidence program, including retrospective claims analyses (3,400+ patients), cohort studies (467 vs. nearly 120,000 patients), an Ontario study (45,000+ patients), and the ROUTE Study (443 participants), generating outcomes data such as 3.5-8.1x lower return-to-use risk and a 62% reduction in bacteremia incidence versus oral buprenorphine.

Indivior generates revenue primarily through prescription pharmaceutical sales distributed via a dedicated commercial field sales force, REMS-certified healthcare settings and pharmacies, criminal justice systems sales infrastructure across 14 states, and international distribution across 37 countries. The go-to-market combines HCP-targeted scientific marketing, direct-to-consumer advertising through Havas (its integrated U.S. agency of record), advocacy partnerships (Mobilize Recovery, Shatterproof, INTO LIGHT Project, NCCHC), and the INSUPPORT patient support program for benefit navigation and copay assistance. Q1 2026 net revenue reached $317 million (+19% YoY), with FY2026 guidance of $1,125-1,195 million, of which SUBLOCADE is expected to contribute $905-945 million. The company employed 1,001-5,000 staff and reported a £1.93 billion market capitalization as of April 5, 2026.

Name

Indivior

Legal name

Indivior Pharmaceuticals, Inc.

Website

http://indivior.com/

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Indivior is a specialty pharmaceutical company focused on opioid use disorder (OUD) treatments, marketing SUBLOCADE (monthly injectable buprenorphine with 75% LAI segment share), SUBOXONE, SUBUTEX, and OPVEE. The company serves healthcare providers, criminal justice systems, and patients across 37 countries via REMS-restricted distribution.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals / Addiction Medicine

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs) (HLAFACAG)

akta.pro secondary industry

Outpatient Substance Use Disorder (SUD) Treatment Programs (HLAFABAD)

Keywords

• Opioid use disorder treatment
• Addiction medicine pharmaceuticals
• Long-acting injectable buprenorphine
• Medication-assisted treatment
• Overdose reversal medications

Headquarters

HQ city

Richmond

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

1. Prescription pharmaceutical sales: Primary revenue stream from sales of prescription opioid use disorder (OUD) medications including SUBLOCADE (extended-release buprenorphine injection), SUBOXONE (buprenorphine/naloxone sublingual film/tablet), and SUBUTEX (buprenorphine sublingual tablet). Q1 2026 total net revenue was $317M (+19% YoY); FY2026 guidance projects $1,125-1,195M in total net revenue with SUBLOCADE expected to generate $905-945M. Sales are driven by healthcare provider prescribing, criminal justice system adoption, and direct-to-consumer promotion.
2. International product sales (37 countries): Revenue from product sales across multiple international markets (Australasia, Europe, North America) including Australia, Canada, France, Germany, UK, Italy, Sweden, Denmark, Finland, Norway, Israel. Indivior announced optimization of Rest of World (ROW) markets in Q3 2025.
3. Opvee/nalmefene nasal spray product sales (discontinued): Revenue from OPVEE nasal spray overdose reversal product; Indivior announced discontinuation of sales and marketing support for OPVEE in Q3 2025 as part of business optimization.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Indivior is a specialty pharmaceutical company that develops, manufactures, and commercializes prescription medications for opioid use disorder (OUD). Its flagship SUBLOCADE is the first FDA-approved once-monthly long-acting injectable buprenorphine for moderate-to-severe OUD, supported by SUBOXONE sublingual film/tablet, SUBUTEX sublingual tablets, and the OPVEE nalmefene nasal spray for opioid overdose reversal. Products are distributed through FDA-mandated REMS-certified channels to healthcare providers, criminal justice systems, and patients across 37 countries.

Product overview

Indivior's offering is a portfolio of branded prescription pharmaceutical products rather than a single unified software platform; the products are organized around the company's singular focus on opioid use disorder (OUD) treatment and adjacent addiction/mental-health indications. The centerpiece is SUBLOCADE®, a once-monthly extended-release buprenorphine injection and the first FDA-approved LAI for moderate-to-severe OUD, which Indivior describes as the leader of its long-acting injectable (LAI) franchise and the focus of its 2026 commercial growth strategy. It is complemented by the transmucosal buprenorphine products SUBOXONE® (sublingual film/tablet, buprenorphine/naloxone) and SUBUTEX® (buprenorphine sublingual tablets in international markets), the overdose-reversal nasal spray OPVEE® (nalmefene), and the discontinued Perseris (risperidone LAI for schizophrenia). The acquired Opiant portfolio (including OPNT003 intranasal nalmefene and the Narcan franchise) extends the offering into opioid overdose reversal. Non-product services include the INSUPPORT patient support program and Indivior Action Agenda–driven commercial and R&D operations.

Differentiator

Problem solved

Functional benefit

Products and services

• SUBLOCADE SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, CIII, is Indivior's flagship once-monthly long-acting injectable (LAI) for the treatment of moderate-to-severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine product. Distributed only through the FDA-mandated SUBLOCADE REMS Program, with 75% LAI segment market share and 191,600 U.S. patients treated over the trailing twelve months ending Q1 2026.
• SUBOXONE (Sublingual Film) SUBOXONE (buprenorphine and naloxone) Sublingual Film, CIII, is a transmucosal buprenorphine/naloxone combination product used for the treatment of opioid dependence, available in the U.S. and other markets, distributed under an FDA-mandated REMS program to reduce risks of accidental overdose, misuse, and abuse.
• SUBOXONE (Sublingual Tablet) Buprenorphine and Naloxone Sublingual Tablet formulation of SUBOXONE, marketed in Canada, Australia, and multiple European countries for the induction and maintenance treatment of opioid dependence.
• SUBUTEX SUBUTEX (buprenorphine) sublingual tablets marketed across various international markets (Australia, Canada, France, Germany, Italy, Nordics, UK) as a treatment for opioid dependence, originally approved by ANSM (France) in 1995 and FDA-approved in the U.S. in 2005 (where it has since been superseded by SUBOXONE).
• OPVEE OPVEE (nalmefene) nasal spray is an opioid overdose reversal agent for emergency treatment of known or suspected opioid overdose. Acquired by Indivior via the Opiant Pharmaceuticals acquisition (completed Q1 2023); Indivior announced plans to discontinue sales and marketing support for OPVEE in 2025 as part of strategic business optimization.
• INSUPPORT Patient Support Program INSUPPORT is Indivior's patient support program providing benefit information, insurance navigation, case-manager assistance, copay help for eligible patients, and other financial-assistance information for accessing Indivior's OUD medications.

Quantifiable outcome

• 3.5 to 8.1 times less likely to return to opioid use for adherent patients on extended-release buprenorphine vs other MOUD groups
• +6 more outcomes

Named customers2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core, minor and flagship.

• Virginia Commonwealth University (VCU) - Rams in RecoverycoreStrategic or Co-development Partner · 20 May 2026Indivior supports VCU's Rams in Recovery collegiate recovery program and participated in VCU Research to Recovery 2026 conference. VCU's OB MOTIVATE team presented on co-located care model for treating OUD during pregnancy. Indivior donated $25,000 to Rams in Recovery - Recovery Scholars Program in 2025.
• External academic and research collaborators (large U.S. claims and EHR-linked datasets)coreStrategic or Co-development Partner · 20 May 2026Indivior funded and conducted real-world evidence studies with external academic and research collaborators using large U.S. claims and electronic health record-linked datasets. Studies published in Drug and Alcohol Dependence Reports (3,400 patient analysis) and The Journal of Substance Use and Addiction Treatment (467 vs 120,000 patient cohort study).
• Veradigm and University of Kentucky College of MedicinecoreImplementation/ SI/ Consulting Partner · 31 March 2026Indivior collaborated with Veradigm and researchers from the University of Kentucky College of Medicine on a cost impact model published in The Journal of Current Medical Research and Opinion estimating that SUBLOCADE (monthly injectable buprenorphine) may reduce staff time and associated costs in jails and prisons. Funded by Indivior.
• National Commission on Correctional Health Care (NCCHC)coreStrategic or Co-development Partner · 11 March 2026Indivior partnered with the NCCHC on a cross-sectional survey of 212 U.S. jails, prisons, and detention centers published in the Journal of Correctional Health Care. The study found only 58% of facilities offer at least one FDA-approved MOUD. Funded by Indivior. The two organizations collaborate to address gaps in MOUD availability and continuity of care.
• HavascoreGTM or Marketing Partner · 24 February 2026Havas appointed as Indivior's integrated U.S. agency of record after a two-month review, consolidating creative, media, and digital responsibilities. Havas previously worked with Indivior through Jacques NY before the account moved to McKinney in 2023. Selection supports accelerated marketing push for Sublocade across HCP and DTC audiences. COMvergence estimates Indivior's 2025 U.S. media spend at $60 million.
• Mobilize RecoverycoreGTM or Marketing Partner · 1 January 2024Indivior supports Mobilize Recovery's mission to expand access to evidence-based treatment and reduce stigma surrounding OUD. Contributions support nationwide recovery events and education initiatives that elevate the voices of people in recovery. 2025 collaboration: $155,000 for 'Mobilizing Advocates for OUD Recovery'. 2025 Campus Initiative donation: $50,000.
• ShatterproofcoreGTM or Marketing Partner · 1 January 2024Indivior partnered with Shatterproof to champion policies and education that treat OUD as a chronic, treatable disease. Charitable support contributes to stigma-reduction campaigns, state-level advocacy, and resources for families navigating treatment. Long-term corporate collaboration amount: $150,000 in 2025.
• INTO LIGHT ProjectminorGTM or Marketing Partner · 1 January 2024Indivior has supported INTO LIGHT Project for multiple years. INTO LIGHT uses art and storytelling to raise awareness of substance use disorder. Contributions: $50,000 (2026), $20,000 (2025 New Hampshire exhibition), $25,800 (2025 Texas exhibition), $60,000 (2025 Wisconsin/Hawaii/Vermont exhibitions).
• Opiant PharmaceuticalsflagshipStrategic or Co-development Partner · 14 November 2022Indivior acquired Opiant Pharmaceuticals for approximately $145 million in upfront cash plus Contingent Value Rights of up to $68 million based on future approvals and revenue. Acquisition aimed to strengthen Indivior's leadership in addiction treatment through Opiant's opioid overdose reversal agent OPNT003 (targeting synthetic opioids like fentanyl). Deal completed in Q1 2023. Expected to be accretive to earnings after the second full year of OPNT003's launch and diversified Indivior's portfolio.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Alkermes plc: Specialty pharmaceutical company whose Vivitrol (monthly injectable naltrexone) directly competes with SUBLOCADE in the long-acting injectable OUD treatment market, targeting the same prescriber base and patient population with a different mechanism of action.
• Braeburn Inc. Markets Brixadi (weekly and monthly injectable buprenorphine), the closest direct competitor to SUBLOCADE in the LAI buprenorphine category, going after the same HCP, criminal justice, and addiction medicine channels.
• Emergent BioSolutions: Owns and commercializes Narcan, the leading over-the-counter opioid overdose reversal nasal spray, directly competing with Indivior's discontinued OPVEE (nalmefene) in the opioid overdose reversal category.
• Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management with a portfolio of abuse-deterrent and CNS products (e.g., Xtampza ER, Jornay PM, Belbuca), making it a comparable small/mid-cap specialty pharma peer with overlapping prescriber channels in controlled substances.
• Mallinckrodt plc: Specialty pharmaceutical company with a controlled substance and addiction medicine portfolio (including generic and branded buprenorphine products), making it a broad incumbent in OUD medication and an active competitor in generic SUBOXONE markets.
• Assertio Holdings: Specialty pharma company with pain and CNS products (e.g., Gralise, Zipsor, Cambia, Sympazan), operating in adjacent controlled-substance and CNS therapeutic categories with a similar small-cap commercial pharma profile.
• Pacira BioSciences: Specialty pharmaceutical company with proprietary long-acting injectable technologies (e.g., EXPAREL, ZILRETTA, iovera) that shares Indivior's strategic focus on long-acting depot injection platforms and controlled substance distribution.

Broad incumbents

• Sandoz (Novartis): Global generics leader offering generic buprenorphine/naloxone products across multiple geographies, providing price-based competition to Indivior's SUBOXONE and SUBUTEX franchises in regulated markets.
• Teva Pharmaceutical Industries: Global pharmaceutical company with a major generics business that supplies generic buprenorphine/naloxone sublingual formulations, directly competing with Indivior's SUBOXONE franchise in the transmucosal OUD category.

Regional players

• Hikma Pharmaceuticals: Specialty and generic pharmaceutical company that markets generic buprenorphine products, particularly in Europe, the Middle East, and select international markets where Indivior distributes SUBUTEX and SUBOXONE.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Indivior
• LinkedInlinkedin.com/company/indivior
• Instagraminstagram.com/lifeatindiviorpharma

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indivior